arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

INSMED Inc

INSM
$108.72 ▼ -1.24 (-1.13%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
67 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

INSMED Inc faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $23.8B
Dividend Yield —
Revenue Growth 268.4% ↘
Op. Margin -17.0% ↘
ROIC -7.2% ↘
FCF / Share $-0.19 ↗
Trailing P/E —
Price / Book 32.8x
FCF Yield —
Debt / Equity 0.75
info Valuation on last close. End-of-day price, Nov 5, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$524.43M
↑ +268.4% —
Net Income Profit after all expenses
$-100.32M
↑ +72.9% —
Operating Margin Operating profit as % of sales
-17.0%
↓ -4584.0% 0th
FCF / Share Free cash flow per share
$-0.19
↑ +56.0% —
Long-Term Debt Long-term obligations
$546.77M
— 0.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
1
Returns ↓
4
Financial Health ↓
32
Cash Quality ↓
51

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 18 years · 67 quarters